MedPath

EPC Performance Investigation for StereoElectroEncephaloGraphy

Recruiting
Conditions
Epilepsy
Registration Number
NCT05223985
Lead Sponsor
Alcis
Brief Summary

The objective of this multicentre study is to collect preoperative, intra operative, early, short, intermediate and mid-term(one years) on the related clinical complications and functional outcomes of market-approved Alcis products to demonstrate safety and performance of these devices in a real-world setting.

Detailed Description

Outcome data collected from this study will provide the basis for Post-Market Surveillance (PMS) reporting, Clinical Study Report (CSR), Clinical Evaluation Report (CER) on Alcis devices and support peer-reviewed publications on products performance and safety.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
74
Inclusion Criteria
  • To be included, patients must be:

  • 18 months to 65 years

  • Patient with drug-resistant and disabling focal epilepsy

  • Informed and willing to sign an informed consent form approved by EC / For minors: if one of the parents cannot consent within the timeframe provided by the protocol, then only one parent's signature is required

  • Affiliation to the social security or foreign regime recognized in France

  • For prospective inclusion: Patient considered for SEEG exploration as part of pre-surgical assessment of epilepsy

  • For ambispective inclusion:

    • Must have undergone an SEEG exploration with one ALCIS device before the date of the initiation visit
    • Follow-up visits (at least 12-month) must be prospective
    • Must have complete information available for each completed visit (demographics, preoperative information, implantation information, device details) *.
Exclusion Criteria
  • • Not able to comply with the study procedures based on the judgment of the assessor (e.g. cannot comprehend study questions, inability to keep scheduled assessment times)

    • Any medical condition that could impact the study at investigator's discretion (e.g. allergy...)
    • Pregnant women (contraindication to SEEG exploration)
    • Adult subject to legal protection measure
    • Skull thickness inferior at 2 mm

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Signal qualitythrough study completion, an average of 10 days".

percentage of contacts that measured a signal

Modification of Electroencephalography trace post-coagulationthrough study completion, an average of 1 hours".

Modification of Electroencephalography trace post-coagulation

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Pôle Investigation - Fondation Adolphe de Rothschild

🇫🇷

Paris, Ile De France, France

Centre d'Investigation Clinique : Equipe Timone Adultes CPCET

🇫🇷

Marseille, France

© Copyright 2025. All Rights Reserved by MedPath